title: A transcatheter arterial chemotherapy using a novel lipophilic platinum derivative (miriplatin) for patients with small and multiple hepatocellular carcinomas.
abstract: OBJECTIVE
  Miriplatin is a platinum complex developed to treat hepatocellular carcinoma (HCC) through administration into the hepatic artery as a sustained-release formulation suspended in lipiodol. A single-institute pilot study was conducted to investigate the antitumor efficacy of miriplatin infusion therapy for small and multiple HCCs.
  
  
  METHODS
  Small HCCs sized 2 cm or less, judged to be inadequate for curative treatment, were indicated for transcatheter arterial miriplatin infusion therapy. We prospectively investigated the course of patients treated with miriplatin between March 2010 and September 2010. Efficacy was evaluated by computed tomography at 4-8 weeks and the overall evaluation was carried out more than 3 months after treatment.
  
  
  RESULTS
  The study included 14 patients, of whom 13 were evaluable for efficacy. Of the 13 patients, one (8%) showed a complete response and three (23%) showed a partial response, with an overall response rate of 31%. Grade 3/4 hematological toxicity including thrombocytopenia was not seen. Increases to grade 3/4 in aspartate aminotransferase and alanine aminotransferase were observed for nonhematological toxicity. Irreversible deleterious changes in hepatic function were not seen.
  
  
  CONCLUSIONS
  Miriplatin infusion therapy showed safe and moderate effects on small HCCs. However, transarterial chemoembolization as a standard therapy cannot be replaced. We await the results of an ongoing study of transarterial chemoembolization with miriplatin.
authors.affiliation: Department of Gastroenterology, Division of Hepatobiliary and Pancreatic Medical Oncology, Cancer Institute Hospital, Tokyo, Japan. syukisawa@yahoo.co.jp
authors.forename: Seigo
authors.initials: S
authors.lastname: Yukisawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishii
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Kasuga
authors.forename: Masato
authors.initials: M
authors.lastname: Matsuyama
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kuraoka
authors.forename: Koichi
authors.initials: K
authors.lastname: Takano
authors.forename: Masato
authors.initials: M
authors.lastname: Ozaka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D003692:Delayed-Action Preparations; D004998:Ethiodized Oil / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D010865:Pilot Projects; D011446:Prospective Studies; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D009944:Organoplatinum Compounds; C406530:miriplatin; D004998:Ethiodized Oil